Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site

  1. Rajendra Uprety
  2. Tao Che
  3. Saheem A Zaidi
  4. Steven G Grinnell
  5. Balázs R Varga
  6. Abdelfattah Faouzi
  7. Samuel T Slocum
  8. Abdullah Allaoa
  9. András Varadi
  10. Melissa Nelson
  11. Sarah M Bernhard
  12. Elizaveta Kulko
  13. Valerie LeRouzic
  14. Shainnel O Eans
  15. Chloe A Simons
  16. Amanda Hunkele
  17. Joan Subrath
  18. Ying Xian Pan
  19. Jonathan A Javitch
  20. Jay P McLaughlin
  21. Bryan L Roth  Is a corresponding author
  22. Gavril W Pasternak
  23. Vsevolod Katritch  Is a corresponding author
  24. Susruta Majumdar  Is a corresponding author
  1. Memorial Sloan Kettering Cancer Center, United States
  2. University of North Carolina, United States
  3. The Bridge Institute, University of Southern California, United States
  4. Columbia University, United States
  5. St. Louis College of Pharmacy and Washington University School of Medicine, United States
  6. Washington University in St. Louis, United States
  7. Washington University, United States
  8. University of Florida, United States
  9. University of Southern California, United States

Abstract

Controlling receptor functional selectivity profiles for opioid receptors is a promising approach for discovering safer analgesics; however, the structural determinants conferring functional selectivity are not well understood. Here we used crystal structures of opioid receptors, including the recently solved active state kappa opioid complex with MP1104, to rationally design novel mixed mu (MOR) and kappa (KOR) opioid receptor agonists with reduced arrestin signaling. Analysis of structure-activity relationships for new MP1104 analogs points to a region between transmembrane 5 (TM5) and extracellular loop (ECL2) as key for modulation of arrestin recruitment to both MOR and KOR. The lead compounds, MP1207 and MP1208, displayed MOR/KOR Gi-partial agonism with diminished arrestin signaling, showed efficient analgesia with attenuated liabilities, including respiratory depression and conditioned place preference and aversion in mice. The findings validate a novel structure-inspired paradigm for achieving beneficial in vivo profiles for analgesia through different mechanisms that include bias, partial agonism, and dual MOR/KOR agonism.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Rajendra Uprety

    Neurology, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    Rajendra Uprety, RU have filed a provisional patent on MP1207 and related molecules..
  2. Tao Che

    Pharmacology, University of North Carolina, Chapel Hill, United States
    Competing interests
    No competing interests declared.
  3. Saheem A Zaidi

    Department of Biological Sciences, Molecular & Computational Biology, The Bridge Institute, University of Southern California, Los Angeles, United States
    Competing interests
    Saheem A Zaidi, SZ has filed a provisional patent on MP1207 and related molecules..
  4. Steven G Grinnell

    Molecular Therapeutics, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  5. Balázs R Varga

    Center for Clinical Pharmacology, St. Louis College of Pharmacy and Washington University School of Medicine, St Louis, United States
    Competing interests
    No competing interests declared.
  6. Abdelfattah Faouzi

    Clinical Pharmacology, Washington University in St. Louis, St Louis, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9059-4791
  7. Samuel T Slocum

    Pharmacology, University of North Carolina, Chapel Hill, United States
    Competing interests
    No competing interests declared.
  8. Abdullah Allaoa

    Neurology, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  9. András Varadi

    Neurology, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5591-377X
  10. Melissa Nelson

    Molecular Therapeutics, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  11. Sarah M Bernhard

    Center for Clinical Pharmacology, Washington University, St Louis, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8549-0413
  12. Elizaveta Kulko

    Molecular Therapeutics, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  13. Valerie LeRouzic

    Neurology, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  14. Shainnel O Eans

    Pharmacodyanamics, University of Florida, Gainesville, United States
    Competing interests
    No competing interests declared.
  15. Chloe A Simons

    Pharmacodyanamics, University of Florida, Gainesville, United States
    Competing interests
    No competing interests declared.
  16. Amanda Hunkele

    Neurology, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  17. Joan Subrath

    Neurology, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    No competing interests declared.
  18. Ying Xian Pan

    Neurology, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    Ying Xian Pan, YXPis a co-founder of Sparian biosciences..
  19. Jonathan A Javitch

    Department of Psychiatry, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7395-2967
  20. Jay P McLaughlin

    Pharmacodyanamics, University of Florida, Gainesville, United States
    Competing interests
    Jay P McLaughlin, JM has filed a provisional patent on MP1207 and related molecules..
  21. Bryan L Roth

    Department of Pharmacology, University of North Carolina, Chapel Hill, United States
    For correspondence
    bryan_roth@med.unc.edu
    Competing interests
    Bryan L Roth, BLR has filed a provisional patent on MP1207 and related molecules..
  22. Gavril W Pasternak

    Neurology, Memorial Sloan Kettering Cancer Center, New York, United States
    Competing interests
    Gavril W Pasternak, GWP is a co-founder of Sparian biosciences. GWP have filed a provisional patent on MP1207 and related molecules..
  23. Vsevolod Katritch

    Department of Biological Sciences, University of Southern California, Los Angeles, United States
    For correspondence
    katritch@usc.edu
    Competing interests
    Vsevolod Katritch, VK has filed a provisional patent on MP1207 and related molecules..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3883-4505
  24. Susruta Majumdar

    Center for Clinical Pharmacology, Washington University, st louis, United States
    For correspondence
    susrutam@email.wustl.edu
    Competing interests
    Susruta Majumdar, SM, is a co-founder of Sparian biosciences. SM have filed a provisional patent on MP1207 and related molecules..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2931-3823

Funding

National Institute on Drug Abuse (DA045884)

  • Susruta Majumdar

National Institute on Drug Abuse (DA045657)

  • Jonathan A Javitch

National Institute on Drug Abuse (DA046487)

  • Susruta Majumdar

National Institute on Alcohol Abuse and Alcoholism (AA026949)

  • Susruta Majumdar

National Institute on Drug Abuse (DA038858)

  • Vsevolod Katritch

National Institute on Drug Abuse (DA035764)

  • Bryan L Roth
  • Vsevolod Katritch

National Institute on Drug Abuse (DA007242,DA006241)

  • Ying Xian Pan
  • Gavril W Pasternak

National Institute on Drug Abuse (DA042888,DA046714)

  • Ying Xian Pan

National Institute of Mental Health (MH018870)

  • Steven G Grinnell

National Institute of Mental Health (MH112205)

  • Jonathan A Javitch

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal studies were preapproved by the Institutional Animal Care and Use Committees of University of Florida in accordance with the 2002 National Institutes of Health Guide for the Care and Use of Laboratory Animals. protocols 201808990 and 202011105.

Copyright

© 2021, Uprety et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,843
    views
  • 788
    downloads
  • 47
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Rajendra Uprety
  2. Tao Che
  3. Saheem A Zaidi
  4. Steven G Grinnell
  5. Balázs R Varga
  6. Abdelfattah Faouzi
  7. Samuel T Slocum
  8. Abdullah Allaoa
  9. András Varadi
  10. Melissa Nelson
  11. Sarah M Bernhard
  12. Elizaveta Kulko
  13. Valerie LeRouzic
  14. Shainnel O Eans
  15. Chloe A Simons
  16. Amanda Hunkele
  17. Joan Subrath
  18. Ying Xian Pan
  19. Jonathan A Javitch
  20. Jay P McLaughlin
  21. Bryan L Roth
  22. Gavril W Pasternak
  23. Vsevolod Katritch
  24. Susruta Majumdar
(2021)
Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site
eLife 10:e56519.
https://doi.org/10.7554/eLife.56519

Share this article

https://doi.org/10.7554/eLife.56519

Further reading

    1. Biochemistry and Chemical Biology
    Parnian Arafi, Sujan Devkota ... Michael S Wolfe
    Research Article

    Missense mutations in the amyloid precursor protein (APP) and presenilin-1 (PSEN1) cause early-onset familial Alzheimer’s disease (FAD) and alter proteolytic production of secreted 38-to-43-residue amyloid β-peptides (Aβ) by the PSEN1-containing γ-secretase complex, ostensibly supporting the amyloid hypothesis of pathogenesis. However, proteolysis of APP substrate by γ-secretase is processive, involving initial endoproteolysis to produce long Aβ peptides of 48 or 49 residues followed by carboxypeptidase trimming in mostly tripeptide increments. We recently reported evidence that FAD mutations in APP and PSEN1 cause deficiencies in early steps in processive proteolysis of APP substrate C99 and that this results from stalled γ-secretase enzyme-substrate and/or enzyme-intermediate complexes. These stalled complexes triggered synaptic degeneration in a Caenorhabditis elegans model of FAD independently of Aβ production. Here, we conducted full quantitative analysis of all proteolytic events on APP substrate by γ-secretase with six additional PSEN1 FAD mutations and found that all six are deficient in multiple processing steps. However, only one of these (F386S) was deficient in certain trimming steps but not in endoproteolysis. Fluorescence lifetime imaging microscopy in intact cells revealed that all six PSEN1 FAD mutations lead to stalled γ-secretase enzyme-substrate/intermediate complexes. The F386S mutation, however, does so only in Aβ-rich regions of the cells, not in C99-rich regions, consistent with the deficiencies of this mutant enzyme only in trimming of Aβ intermediates. These findings provide further evidence that FAD mutations lead to stalled and stabilized γ-secretase enzyme-substrate and/or enzyme-intermediate complexes and are consistent with the stalled process rather than the products of γ-secretase proteolysis as the pathogenic trigger.

    1. Biochemistry and Chemical Biology
    2. Chromosomes and Gene Expression
    Kira A Cozzolino, Lynn Sanford ... Dylan J Taatjes
    Research Article

    Hyperactive interferon (IFN) signaling is a hallmark of Down syndrome (DS), a condition caused by Trisomy 21 (T21); strategies that normalize IFN signaling could benefit this population. Mediator-associated kinases CDK8 and CDK19 drive inflammatory responses through incompletely understood mechanisms. Using sibling-matched cell lines with/without T21, we investigated Mediator kinase function in the context of hyperactive IFN in DS over a 75 min to 24 hr timeframe. Activation of IFN-response genes was suppressed in cells treated with the CDK8/CDK19 inhibitor cortistatin A (CA), via rapid suppression of IFN-responsive transcription factor (TF) activity. We also discovered that CDK8/CDK19 affect splicing, a novel means by which Mediator kinases control gene expression. To further probe Mediator kinase function, we completed cytokine screens and metabolomics experiments. Cytokines are master regulators of inflammatory responses; by screening 105 different cytokine proteins, we show that Mediator kinases help drive IFN-dependent cytokine responses at least in part through transcriptional regulation of cytokine genes and receptors. Metabolomics revealed that Mediator kinase inhibition altered core metabolic pathways in cell type-specific ways, and broad upregulation of anti-inflammatory lipid mediators occurred specifically in kinase-inhibited cells during hyperactive IFNγ signaling. A subset of these lipids (e.g. oleamide, desmosterol) serve as ligands for nuclear receptors PPAR and LXR, and activation of these receptors occurred specifically during hyperactive IFN signaling in CA-treated cells, revealing mechanistic links between Mediator kinases, lipid metabolism, and nuclear receptor function. Collectively, our results establish CDK8/CDK19 as context-specific metabolic regulators, and reveal that these kinases control gene expression not only via TFs, but also through metabolic changes and splicing. Moreover, we establish that Mediator kinase inhibition antagonizes IFN signaling through transcriptional, metabolic, and cytokine responses, with implications for DS and other chronic inflammatory conditions.